Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Immunovia AB ( (SE:IMMNOV) ) just unveiled an update.
Immunovia AB is set to launch its PancreaSure test in the US on September 2nd, marking a significant milestone in its commercial strategy. The company plans a phased rollout, initially focusing on building advocacy among key opinion leaders and high-risk surveillance centers, followed by expanding its reach through strategic partnerships and securing insurance reimbursement by 2026. The test, priced at $995, will be available at a reduced cost for prompt payments and through a financial assistance program. This launch is expected to enhance Immunovia’s market positioning and potentially increase early detection rates of pancreatic cancer.
More about Immunovia AB
Immunovia AB is a diagnostic company focused on increasing survival rates for pancreatic cancer patients through early detection. The company specializes in developing and commercializing simple tests to detect proteins and blood-based antibodies indicative of pancreatic cancer. Immunovia collaborates with healthcare providers, experts, and advocacy groups to make its tests available to high-risk individuals. The USA is the largest market for pancreatic cancer detection, with an estimated 1.8 million high-risk individuals who could benefit from annual surveillance testing.
Average Trading Volume: 6,669,453
Technical Sentiment Signal: Sell
Current Market Cap: SEK169.9M
For an in-depth examination of IMMNOV stock, go to TipRanks’ Overview page.